Developing Immunotherapies that Target the Drivers of Cancer

Jak Knowles, CEO of Affini-T Therapeutics, discusses the company’s TCR-T cell therapies that target the drivers of a cancer, how they are engineered, and why they have the potential to be effective at treating solid tumors that have evaded the power of CAR T therapies.